8-K ·Filed Jun 10, 2026

ABEO

ABEONA THERAPEUTICS INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed3mo ago SEC0001493152-26-028106
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The investor presentation is a routine corporate update with no new material information. Monitor for future SEC filings containing clinical pipeline updates, financial results, or regulatory catalysts for the pz-cel program.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
ABEO ▲ +28.75% at T+20d
NEUTRAL call ✓ call won +28.75% · α vs SPY +26.86% · entry $5.53 → $7.12
Next anchor: T+60d due 28d ago
Latest observation: T+57 +12.51% FF3 residual α
Entry anchored
Jun 10, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α -0.54%
$5.53
settled 4mo ago
T+5d
+2.17%
call +2.17% · α +1.74%
$5.65
settled 4mo ago
T+20d
+28.75%
call +28.75% · α +26.86%
$7.12
settled 3mo ago
T+60d
—
call — · α —
—
due 28d ago

Price Chart

Loading chart...

Executive Summary

Abeona Therapeutics filed an 8-K furnishing an updated investor presentation (Exhibit 99.1) under Item 7.01 for use in meetings with investors and analysts. No material financial data, guidance updates, or business developments were disclosed — this is a routine disclosure of a corporate presentation used for investor relations.

Key Facts

  • Filed an 8-K on June 10, 2026 furnishing an updated investor presentation under Item 7.01.
  • The presentation is dated June 10, 2026 and is attached as Exhibit 99.1.
  • No financial results, guidance, material agreements, or operational updates were disclosed.
  • The filing is a routine Regulation FD disclosure for use in investor meetings.

Financial Impact

No financial impact — no material financial data or guidance was provided.

Risk Factors

  • No material information disclosed — the presentation may contain forward-looking statements with standard risk factors.
  • Biotech sector risks including clinical trial setbacks, regulatory delays, and capital needs.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-028106
Document: 0001493152-26-028106-index-headers.html0001493152-26-028106
Document: 0001493152-26-028106-index.html0001493152-26-028106
Document: 0001493152-26-028106.txt0001493152-26-028106
19 reports for ABEO
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+1▲ +3.70%Aug 14, 2026
Filters
Rows
Reports for ABEO — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
8-K
NEUTRAL ★ 2/10
$5.47 $5.57▲ +1.83%▲ +1.01%$5.03 (−8.14%)
Aug 14, 2026
6w ago
Institutional Cluster
BULLISH ★ 5/10
$5.94 $6.06▲ +2.02%▲ +3.21%$5.03 (−15.40%)
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$6.35 $5.96▼ −6.07%▼ −4.10%$5.03 (−20.80%)
Aug 13, 2026
7w ago
Press Release
MIXED ★ 6/10
$6.35 $5.96▼ −6.07%▼ −4.10%$5.03 (−20.80%)
Jul 9, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$6.98 $7.02▲ +0.57%▲ +1.13%$5.03 (−28.01%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 4/10
$5.65 $5.72▲ +1.24%▲ +3.47%$5.03 (−11.06%)
Jun 15, 2026
15w ago
Insider Cluster
BEARISH ★ 5/10
$5.65 $5.72▼ −1.24%▼ −3.47%$5.03 (+11.06%)
Jun 12, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$5.53 $5.77▲ +4.34%▲ +3.67%$5.03 (−9.13%)
Jun 10, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$5.53 $5.65▲ +2.17%▲ +1.74%$5.03 (−9.13%)
Jun 10, 2026
16w ago
Insider Cluster
BEARISH ★ 5/10
$5.36 $5.65▼ −5.41%▼ −1.98%$5.03 (+6.25%)
Showing 10 of 19

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access